טוען...

Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial

We describe the results from a human clinical trial of a dengue virus serotype-1, purified-inactivated vaccine (DENV-1 PIV) adjuvanted with aluminum hydroxide. This first-in-man, Phase 1, open-label clinical trial consisted of two groups of flavivirus-naïve healthy adult volunteers that received two...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Am J Trop Med Hyg
Main Authors: Martinez, Luis Javier, Lin, Leyi, Blaylock, Jason M., Lyons, Arthur G., Bauer, Kristen M., De La Barrera, Rafael, Simmons, Monika, Jarman, Richard G., Currier, Jeffrey R., Friberg, Heather, Danko, Janine R., Teneza-Mora, Nimfa C., Putnak, J. Robert, Eckels, Kenneth H., Thomas, Stephen J.
פורמט: Artigo
שפה:Inglês
יצא לאור: The American Society of Tropical Medicine and Hygiene 2015
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4559679/
https://ncbi.nlm.nih.gov/pubmed/26149862
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4269/ajtmh.14-0819
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!